Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen
Pharma
Apellis hit with yet another eye drug snub in Europe
Amid a parade of regulatory endorsements in Europe, Apellis’ ophthalmology prospect pegcetacoplan has been left in the cold once again.
Fraiser Kansteiner
Sep 20, 2024 10:06am
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm
Sanofi, DualityBio, UCB—Fierce Pharma Asia
Aug 30, 2024 8:05am
FDA approves Gilead's Livdelzi for primary biliary cholangitis
Aug 14, 2024 3:29pm
Ipsen secures ex-US rights to Day One's pediatric cancer med
Jul 25, 2024 10:05am
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
